FLT1 and Nephropathy: Here, we investigated whether the VEGF-A inhibitor soluble FLT-1 (sFLT-1; also known as soluble VEGFR-1) can reduce renal complications, including albuminuria and mesangial matrix expansion, in a mouse model of type 1 diabetes and pre-existing kidney damage.